pyroxamide

Pyroxamide is a synthetic small molecule and potent inhibitor of histone deacetylases (HDACs), particularly HDAC1. It is a derivative of hydroxamic acid with antineoplastic properties. Pyroxamide induces hyperacetylation of core histones, modulating chromatin structure and affecting the transcription of genes involved in tumor growth inhibition. This leads to cell cycle arrest, terminal differentiation, and apoptosis in various cancer cell lines. Pyroxamide has been investigated primarily for the treatment of cancers such as leukemia, lymphoma, small intestine cancer, myelodysplastic syndromes, and other malignancies[1][2][3][4]. The drug was originally developed by Aton Pharma and later acquired by Merck & Co., but its clinical development was discontinued after phase 1 trials for cancer[5].

Other names

N-hydroxy-N'-(pyridin-3-yl)octanediamideN'-hydroxy-N-pyridin-3-yloctanediamidesuberoyl-3-aminopyridineamide hydroxamic acidsuberoyl3-aminopyridineamide hydroxamic acidsuberoyl 3-aminopyridineamide hydroxamic acidOctanediamide, N-hydroxy-N'-3-pyridinyl-